| ［1］ |
中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
|
| ［2］ |
Chovatiya R, Silverberg JI. Association of herpes zoster and chronic inflammatory skin disease in US inpatients［J］. J Am Acad Dermatol, 2021,85（6）:1437⁃1445. doi: 10.1016/j.jaad.2019. 12.073.
|
| ［3］ |
De SK. Abrocitinib: first globally approved selective Janus kinase⁃1 inhibitor for the treatment of atopic dermatitis［J］. Curr Med Chem, 2023,30（38）:4278⁃4282. doi: 10.2174/09298673306662 30216123419.
|
| ［4］ |
Juczynska K, Wozniacka A, Waszczykowska E, et al. Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris［J］. Immunol Res, 2020,68（2）:97⁃103. doi: 10.1007/s12026⁃020⁃09122⁃y.
|
| ［5］ |
Tavakolpour S. Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus［J］. Dermatol Ther, 2018,31（5）:e12696. doi: 10.1111/dth.12696.
|
| ［6］ |
骆彦霏, 王远志, 符文好, 等. 巴瑞替尼联合糖皮质激素治疗天疱疮的疗效及安全性评价［J］. 中国皮肤性病学杂志, 2024,38（4）:409⁃413. doi: 10.13735/j.cjdv.1001⁃7089.202303123.
|
| ［7］ |
Guenin S, Shah S, Lebwohl M. Oral Jak inhibitor upadacitinib use in treatment of pemphigus foliaceus: case report［J］. SKIN, 2023, 7（4）: 881⁃885. doi:10.25251/skin.7.4.5.
|
